Compare Biogen Inc (BIIB) vs SOLAI Limited (SLAI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs SOLAI Limited — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while SOLAI Limited trades at $3.72 (market cap $16.69M). The key difference: Biogen Inc is far larger — about 1805.3× SOLAI Limited's market cap, and Biogen Inc is trading nearer its 52-week high, SOLAI Limited nearer its low. Which is the better fit depends on your goals.
| BIIB | SLAI | |
|---|---|---|
Market Cap | $30.13B | $16.69M |
Sector | Health | Technology |
52-Week High | $216.63 | $26.74 |
52-Week Low | $132.22 | $2.74 |
Enterprise Value | $37.20B | $16.33M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
SLAI trades at $3.72 with no recent price movement, showing mixed technical signals despite a bullish overall rating. The company faces severe financial distress with negative profit margins (-134.63% net income margin) and declining revenue, compounded by NYSE delisting proceedings initiated in July 2026. Recent corporate actions include a 7:1 reverse stock split completed in July 2026 and the acquisition of a 51% stake in NEURALAND, signaling strategic shifts amid operational challenges.
The outlook remains highly speculative with significant execution and liquidity risks. While technical indicators suggest potential short-term momentum, fundamental weaknesses and delisting uncertainty create substantial downside risk. Investors should approach with caution given the company's negative profitability and regulatory challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
